SCHEMBL29630199

SCHEMBL29630199

Cc1ncc(COc2ccc3oc(C)c(C(=O)NC4(C(=O)O)CCC4)c3c2)s1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
SLC26A4 O43511 7/20 0.44
KMT2A Q03164 7/20 0.43
MEN1 O00255 6/20 0.43
LMNA P02545 3/20 0.43
BLM P54132 1/20 0.43
ATM Q13315 1/20 0.43
HTT P42858 1/20 0.43
GAA P10253 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 4/20 0.42
TSHR P16473 2/20 0.42
POLB P06746 2/20 0.42
ROCK1 Q13464 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24485156 0.92 GAA (0.45) CASP3SENP8SENP7SENP6SLC26A4
SCHEMBL29629918 0.92 GAA (0.45) CASP3SENP8SENP7SENP6SLC26A4
SCHEMBL29629997 0.91 KMT2A (0.42) CASP3SENP8SENP7SENP6SLC26A4
SCHEMBL24484860 0.91 KMT2A (0.42) CASP3SENP8SENP7SENP6SLC26A4
SCHEMBL29629992 0.89 GAA (0.46) CASP3SENP8SENP7SENP6SLC26A4
SCHEMBL24485172 0.89 GAA (0.46) CASP3SENP8SENP7SENP6SLC26A4
SCHEMBL24485715 0.88 GAA (0.43) CASP3SENP8SENP7SENP6SLC26A4
SCHEMBL29630128 0.88 GAA (0.43) CASP3SENP8SENP7SENP6SLC26A4
SCHEMBL24484477 0.86 LMNA (0.42) CASP3SENP8SENP7SENP6SLC26A4
SCHEMBL24485415 0.86 GAA (0.41) CASP3SENP8SENP7SENP6SLC26A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-01-28 US disclosed
WO-2022112352-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders TRPM4, TRPM6, TRPM2 CASP3 403/4885SENP8 3515/4885SENP7 4185/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.